439208147	439208147	CD	B-NP	O
|	|	NN	I-NP	O
ALH	ALH	NN	I-NP	O
|	|	NN	I-NP	O
68446510	68446510	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
3389626	3389626	CD	B-NP	O
|	|	CC	I-NP	O
6/21/2006	6/21/2006	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	O
pneumonia	pneumonia	NN	I-NP	O
|	|	NN	I-NP	O
Signed	Signed	NNP	I-NP	O
|	|	NNP	I-NP	O
DIS	DIS	NNP	I-NP	O
|	|	NNP	I-NP	O
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
9/3/2006	9/3/2006	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Signed	Signed	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
8/30/2006	8/30/2006	CD	B-NP	O
ATTENDING	ATTENDING	NN	I-NP	O
:	:	:	O	O
CZACHOR	CZACHOR	NN	B-NP	O
,	,	,	O	O
FREDDY	FREDDY	NNP	B-NP	O
MD	MD	NNP	I-NP	O
,	,	,	O	O
MBA	MBA	NNP	B-NP	O
PRINCIPAL	PRINCIPAL	NNP	I-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
diagnosis	diagnosis	NN	I-NP	O
responsible	responsible	JJ	B-ADJP	O
for	for	IN	B-PP	O
causing	cause	VBG	B-VP	O
the	the	DT	B-NP	O
admission	admission	NN	I-NP	O
is	be	VBZ	B-VP	O
pleural	pleural	JJ	B-NP	O
effusions	effusion	NNS	I-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
:	:	:	O	O
Pleural	Pleural	JJ	B-NP	O
effusions	effusion	NNS	I-NP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
congestive	congestive	JJ	B-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
.	.	.	O	O

CHIEF	CHIEF	NN	B-NP	B-protein
COMPLAINT	COMPLAINT	NN	I-NP	O
:	:	:	O	O
Shortness	Shortness	NN	B-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
.	.	.	O	O

HISTORY	HISTORY	NN	B-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	JJ	B-NP	O
ILLNESS	ILLNESS	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
an	an	DT	B-NP	O
86-year-old	86-year-old	JJ	I-NP	O
male	male	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
congestive	congestive	JJ	B-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
,	,	,	O	O
coronary	coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
,	,	,	O	O
chronic	chronic	JJ	B-NP	O
renal	renal	JJ	I-NP	O
insufficiency	insufficiency	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
non-small	non-small	JJ	B-NP	O
cell	cell	NN	I-NP	O
carcinoma	carcinoma	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
lung	lung	NN	I-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
resection	resection	NN	I-NP	O
in	in	IN	B-PP	O
1997	1997	CD	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
presents	present	VBZ	B-VP	O
with	with	IN	B-PP	O
shortness	shortness	NN	B-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
lives	live	VBZ	B-VP	O
in	in	IN	B-PP	O
a	a	DT	B-NP	O
nursing	nursing	NN	I-NP	O
home	home	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
diagnosed	diagnose	VBN	I-VP	O
with	with	IN	B-PP	O
pneumonia	pneumonia	NN	B-NP	O
more	more	JJR	B-NP	O
than	than	IN	I-NP	O
three	three	CD	I-NP	O
weeks	week	NNS	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
pneumonia	pneumonia	NN	I-NP	O
,	,	,	O	O
per	per	IN	B-PP	O
report	report	NN	B-NP	O
,	,	,	O	O
was	be	VBD	B-VP	O
bilateral	bilateral	JJ	B-ADJP	O
,	,	,	O	O
left	leave	VBD	B-VP	O
greater	great	JJR	B-ADJP	O
than	than	IN	B-PP	O
right	right	JJ	B-ADJP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
10-day	10-day	JJ	I-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
he	he	PRP	B-NP	O
completed	complete	VBD	B-VP	O
.	.	.	O	O

He	He	PRP	B-NP	O
subsequently	subsequently	RB	B-ADVP	O
developed	develop	VBD	B-VP	O
C.	C.	NNP	B-NP	O
diff	diff	NN	I-NP	O
colitis	colitis	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
Flagyl	Flagyl	NN	B-NP	O
.	.	.	O	O

Three	Three	CD	B-NP	O
days	day	NNS	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
present	present	JJ	I-NP	O
admission	admission	NN	I-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
noticing	notice	VBG	B-VP	O
increased	increase	VBN	B-NP	O
shortness	shortness	NN	I-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
,	,	,	O	O
worsened	worsen	VBD	B-VP	O
with	with	IN	B-PP	O
any	any	DT	B-NP	O
movement	movement	NN	I-NP	O
in	in	IN	B-PP	O
bed	bed	NN	B-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
chest	ch	JJS	I-NP	O
x-ray	x-ray	NN	I-NP	B-DNA
at	at	IN	B-PP	O
the	the	DT	B-NP	O
nursing	nursing	NN	I-NP	O
home	home	NN	I-NP	O
reportedly	reportedly	RB	B-ADVP	O
showed	show	VBD	B-VP	O
an	an	DT	B-NP	O
increased	increase	VBN	I-NP	O
opacity	opacity	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
right	right	JJ	I-NP	O
lower	low	JJR	I-NP	O
base	base	NN	I-NP	O
,	,	,	O	O
concerning	concern	VBG	B-VP	O
for	for	IN	B-PP	O
recurrent	recurrent	JJ	B-NP	O
pneumonia	pneumonia	NN	I-NP	O
.	.	.	O	O

For	For	IN	B-PP	O
this	this	DT	B-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
restarted	restart	VBN	I-VP	O
on	on	IN	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
the	the	DT	B-NP	O
day	day	NN	I-NP	O
of	of	IN	B-PP	O
admission	admission	NN	B-NP	O
,	,	,	O	O
his	his	PRP$	B-NP	O
oxygen	oxygen	NN	I-NP	O
saturation	saturation	NN	I-NP	O
dropped	drop	VBD	B-VP	O
to	to	TO	B-PP	O
77	77	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
,	,	,	O	O
with	with	IN	B-PP	O
improvement	improvement	NN	B-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
mid	mid	JJ	I-NP	O
90	90	CD	I-NP	O
's	's	POS	B-NP	O
on	on	IN	B-PP	O
3	3	CD	B-NP	O
liters	liter	NNS	I-NP	O
of	of	IN	B-PP	O
oxygen	oxygen	NN	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
noted	note	VBD	B-VP	O
a	a	DT	B-NP	O
mild	mild	JJ	I-NP	O
dry	dry	JJ	I-NP	O
cough	cough	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
denied	deny	VBN	I-NP	O
headache	headache	NN	I-NP	O
,	,	,	O	O
dizziness	dizziness	NN	B-NP	O
,	,	,	O	O
chest	chest	NN	B-NP	O
pain	pain	NN	I-NP	O
,	,	,	O	O
hemoptysis	hemoptysis	NN	B-NP	O
,	,	,	O	O
abdominal	abdominal	JJ	B-NP	O
discomfort	discomfort	NN	I-NP	O
,	,	,	O	O
or	or	CC	O	O
dysuria	dysuria	NN	B-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
son	son	NN	I-NP	O
reported	report	VBD	B-VP	O
that	that	IN	B-SBAR	O
he	he	PRP	B-NP	O
has	have	VBZ	B-VP	O
mild	mild	JJ	B-NP	O
orthopnea	orthopnea	NN	I-NP	O
at	at	IN	B-PP	O
baseline	baseline	NN	B-NP	O
,	,	,	O	O
unchanged	unchanged	JJ	B-ADJP	O
in	in	IN	B-PP	O
recent	recent	JJ	B-NP	O
days	day	NNS	I-NP	O
.	.	.	O	O

Notably	Notably	RB	B-ADVP	O
,	,	,	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
Sho	Sho	NNP	I-NP	O
Hospital	Hospital	NNP	I-NP	O
in	in	IN	B-PP	O
5/23	5/23	CD	B-NP	O
for	for	IN	B-PP	O
subacute	subacute	JJ	B-NP	O
shortness	shortness	NN	I-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
,	,	,	O	O
thought	think	VBN	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
due	due	IN	B-PP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
CHF	CHF	NN	I-NP	O
exacerbation	exacerbation	NN	I-NP	O
,	,	,	O	O
treated	treat	VBN	B-VP	O
with	with	IN	B-PP	O
Lasix	Lasix	NN	B-NP	O
diuresis	diuresis	NN	I-NP	O
.	.	.	O	O

An	An	DT	B-NP	O
echocardiogram	echocardiogram	NN	I-NP	O
at	at	IN	B-PP	O
that	that	DT	B-NP	O
time	time	NN	I-NP	O
showed	show	VBD	B-VP	O
an	an	DT	B-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
of	of	IN	B-PP	O
55	55	CD	B-NP	O
%	%	NN	I-NP	O
,	,	,	O	O
with	with	IN	B-PP	O
mild	mild	JJ	B-NP	O
left	left	JJ	I-NP	O
atrial	atrial	JJ	I-NP	O
enlargement	enlargement	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
mild	mild	JJ	B-NP	O
concentric	concentric	JJ	I-NP	O
left	left	JJ	I-NP	O
ventricular	ventricular	JJ	I-NP	O
hypertrophy	hypertrophy	NN	I-NP	O
,	,	,	O	O
along	along	IN	B-PP	O
with	with	IN	B-PP	O
inferobasal	inferobasal	JJ	B-NP	O
wall	wall	NN	I-NP	O
hypokinesis	hypokinesis	NN	I-NP	O
.	.	.	O	O

REVIEW	REVIEW	NNP	B-NP	O
OF	OF	IN	B-PP	O
SYSTEMS	SYSTEMS	NNP	B-NP	O
:	:	:	O	O
As	As	IN	B-PP	O
above	above	IN	B-PP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
present	present	JJ	B-NP	O
illness	illness	NN	I-NP	O
,	,	,	O	O
along	along	IN	B-PP	O
with	with	IN	B-PP	O
constipation	constipation	NN	B-NP	O
,	,	,	O	O
pain	pain	NN	B-NP	O
with	with	IN	B-PP	O
movement	movement	NN	B-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
right	right	JJ	I-NP	O
knee	knee	NN	I-NP	O
and	and	CC	I-NP	O
right	right	JJ	I-NP	O
heel	heel	NN	I-NP	O
ulcer	ulcer	NN	I-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
skin	skin	NN	I-NP	O
graft	graft	NN	I-NP	O
.	.	.	O	O

PAST	PAST	NNP	B-NP	O
MEDICAL	MEDICAL	NNP	I-NP	O
HISTORY	HISTORY	NNP	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

Congestive	Congestive	JJ	B-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
,	,	,	O	O
ejection	ejection	NN	B-NP	O
fraction	fraction	NN	I-NP	O
55	55	CD	B-NP	O
%	%	NN	I-NP	O
,	,	,	O	O
concentric	concentric	JJ	B-NP	O
LV	LV	NN	I-NP	O
hypertrophy	hypertrophy	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Coronary	Coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	VBD	B-VP	O
multiple	multiple	JJ	B-NP	O
angioplasties	angioplasty	NNS	I-NP	O
of	of	IN	B-PP	O
LAD	LAD	NN	B-NP	B-protein
and	and	CC	O	O
left	left	JJ	B-NP	O
circumflex	circumflex	NN	I-NP	O
in	in	IN	B-PP	O
mid	mid	NN	B-NP	O
1990	1990	CD	I-NP	O
's	's	POS	B-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Non-small	Non-small	JJ	B-NP	O
cell	cell	NN	I-NP	O
carcinoma	carcinoma	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
lung	lung	NN	I-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
resection	resection	NN	I-NP	O
in	in	IN	B-PP	O
1997	1997	CD	B-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Atrial	Atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
,	,	,	O	O
diagnosed	diagnose	VBN	B-VP	O
in	in	IN	B-PP	O
2005	2005	CD	B-NP	O
,	,	,	O	O
on	on	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Diabetes	Diabetes	NN	B-NP	O
mellitus	mellitus	NN	I-NP	O
,	,	,	O	O
diagnosed	diagnose	VBN	B-VP	O
more	more	JJR	B-NP	O
than	than	IN	I-NP	O
20	20	CD	I-NP	O
years	year	NNS	I-NP	O
ago	ago	RB	B-ADVP	O
,	,	,	O	O
on	on	IN	B-PP	O
insulin	insulin	NN	B-NP	B-protein
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Chronic	Chronic	JJ	B-NP	O
renal	renal	JJ	I-NP	O
insufficiency	insufficiency	NN	I-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Peripheral	Peripheral	JJ	B-NP	O
vascular	vascular	JJ	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
angioplasty	angioplasty	NN	I-NP	O
in	in	IN	B-PP	O
2006	2006	CD	B-NP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Osteoarthritis	Osteoarthritis	NN	B-NP	O
,	,	,	O	O
worst	worst	JJS	B-ADJP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
right	right	JJ	I-NP	O
knee	knee	NN	I-NP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Hypothyroidism	Hypothyroidism	NN	B-NP	O
.	.	.	O	O

10	10	CD	B-NP	O
.	.	.	O	O

BPH	BPH	NN	B-NP	O
,	,	,	O	O
status	status	NN	B-NP	B-protein
post	post	NN	I-NP	I-protein
TURP	TURP	NN	I-NP	I-protein
,	,	,	O	O
1988	1988	CD	B-NP	O
.	.	.	O	O

11	11	CD	B-NP	O
.	.	.	O	O

Status	Status	NNP	B-NP	O
post	post	NN	I-NP	O
appendectomy	appendectomy	NN	I-NP	O
.	.	.	O	O

12	12	CD	B-NP	O
.	.	.	O	O

Right	Right	NN	B-NP	O
heel	heel	NN	I-NP	O
ulcer	ulcer	NN	I-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
skin	skin	NN	I-NP	O
graft	graft	NN	I-NP	O
.	.	.	O	O

13	13	CD	B-NP	O
.	.	.	O	O

Gout	Gout	NNP	B-NP	O
.	.	.	O	O

MEDICATIONS	MEDICATIONS	NNS	B-NP	O
ON	ON	NN	I-NP	O
ADMISSION	ADMISSION	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Digoxin	Digoxin	NN	B-NP	O
0.125	0.125	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Metoprolol	Metoprolol	NN	B-NP	O
25	25	CD	I-NP	O
mg	mg	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
3	3	CD	I-NP	O
.	.	.	O	O

Lasix	Lasix	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Levofloxacin	Levofloxacin	NN	B-NP	O
750	750	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Coumadin	Coumadin	NN	B-NP	O
3	3	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Colchicine	Colchicine	NN	B-NP	O
0.6	0.6	CD	I-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-NP	O
7	7	CD	I-NP	O
.	.	.	O	O

Prilosec	Prilosec	RB	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Zocor	Zocor	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Questran	Questran	NN	B-NP	O
2	2	CD	I-NP	O
mg	mg	NN	I-NP	O
twice	twice	RB	B-NP	O
a	a	DT	I-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

10	10	CD	B-NP	O
.	.	.	O	O

Aspirin	Aspirin	NN	B-NP	O
81	81	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

11	11	CD	B-NP	O
.	.	.	O	O

Iron	Iron	NN	B-NP	O
sulfate	sulfate	NN	I-NP	O
325	325	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

12	12	CD	B-NP	O
.	.	.	O	O

Neurontin	Neurontin	NN	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
q.a.m.	q.a.m.	NN	I-NP	O
and	and	CC	O	O
200	200	CD	B-NP	O
mg	mg	NN	I-NP	O
q.p.m.	q.p.m.	NN	I-NP	O
13	13	CD	I-NP	O
.	.	.	O	O

Flomax	Flomax	NN	B-NP	O
0.4	0.4	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

14	14	CD	B-NP	O
.	.	.	O	O

Zoloft	Zoloft	NNP	B-NP	O
50	50	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

15	15	CD	B-NP	O
.	.	.	O	O

Synthroid	Synthroid	JJ	B-NP	O
25	25	CD	I-NP	O
mcg	mcg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

16	16	CD	B-NP	O
.	.	.	O	O

Lantus	Lantus	NNP	B-NP	O
32	32	CD	I-NP	O
units	unit	NNS	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

17	17	CD	B-NP	O
.	.	.	O	O

NovoLog	NovoLog	NN	B-NP	O
6	6	CD	B-NP	O
units	unit	NNS	I-NP	O
q.a.c.	q.a.c.	NN	B-NP	O
18	18	CD	I-NP	O
.	.	.	O	O

Colace	Colace	NNP	B-NP	O
.	.	.	O	O

19	19	CD	B-NP	O
.	.	.	O	O

Senna	Senna	NNP	B-NP	O
.	.	.	O	O

20	20	CD	B-NP	O
.	.	.	O	O

Tylenol	Tylenol	NN	B-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
21	21	CD	I-NP	O
.	.	.	O	O

Dilaudid	Dilaudid	JJ	B-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
ALLERGIES	ALLERGIES	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
allergic	allergic	JJ	B-ADJP	O
to	to	TO	B-PP	O
penicillin	penicillin	NN	B-NP	B-protein
,	,	,	O	O
which	which	WDT	B-NP	O
causes	cause	VBZ	B-VP	O
a	a	DT	B-NP	O
rash	rash	NN	I-NP	O
.	.	.	O	O

SOCIAL	SOCIAL	JJ	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
He	He	PRP	B-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
living	live	VBG	I-VP	O
in	in	IN	B-PP	O
a	a	DT	B-NP	O
nursing	nursing	NN	I-NP	O
home	home	NN	I-NP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
last	last	JJ	I-NP	O
month	month	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
son	son	NN	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
neurologist	neurologist	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
smoked	smoke	VBD	B-VP	O
cigars	cigar	NNS	B-NP	O
for	for	IN	B-PP	O
many	many	JJ	B-NP	O
years	year	NNS	I-NP	O
,	,	,	O	O
currently	currently	RB	B-ADVP	O
a	a	DT	B-NP	O
nonsmoker	nonsmoker	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	B-protein
denies	deny	VBZ	B-VP	O
any	any	DT	B-NP	O
alcohol	alcohol	NN	I-NP	O
or	or	CC	I-NP	O
illicit	illicit	JJ	I-NP	O
drug	drug	NN	I-NP	O
use	use	NN	I-NP	O
.	.	.	O	O

FAMILY	FAMILY	NN	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
Notable	Notable	JJ	B-ADJP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
father	father	NN	I-NP	O
with	with	IN	B-PP	O
diabetes	diabetes	NN	B-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
brother	brother	NN	I-NP	O
with	with	IN	B-PP	O
heart	heart	NN	B-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

SUMMARY	SUMMARY	NN	B-NP	O
OF	OF	IN	B-PP	O
THE	THE	DT	B-NP	O
HOSPITAL	HOSPITAL	JJ	I-NP	O
COURSE	COURSE	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Shortness	Shortness	NN	B-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
initially	initially	RB	B-ADVP	O
presented	present	VBD	B-VP	O
with	with	IN	B-PP	O
shortness	shortness	NN	B-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
,	,	,	O	O
saturating	saturate	VBG	B-VP	O
77	77	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
on	on	IN	B-PP	O
chest	chest	NN	B-NP	O
x-ray	x-ray	NN	I-NP	O
to	to	TO	B-VP	O
have	have	VB	I-VP	O
moderate	moderate	JJ	B-NP	O
bilateral	bilateral	JJ	I-NP	O
effusions	effusion	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
effusions	effusion	NNS	I-NP	O
were	be	VBD	B-VP	O
likely	likely	RB	B-ADJP	O
secondary	secondary	JJ	I-ADJP	O
to	to	TO	B-PP	O
congestive	congestive	JJ	B-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
,	,	,	O	O
although	although	IN	B-SBAR	O
pneumonia	pneumonia	NN	B-NP	O
with	with	IN	B-PP	O
parapneumonic	parapneumonic	JJ	B-NP	O
effusions	effusion	NNS	I-NP	O
could	could	MD	B-VP	O
not	not	RB	I-VP	O
be	be	VB	I-VP	O
excluded	exclude	VBN	I-VP	O
.	.	.	O	O

Given	Give	VBN	B-VP	O
that	that	IN	B-SBAR	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
afebrile	afebrile	JJ	B-ADJP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
decreasing	decrease	VBG	I-NP	O
white	white	JJ	I-NP	O
count	count	NN	I-NP	O
and	and	CC	O	O
not	not	RB	B-NP	O
increasingly	increasingly	RB	I-NP	O
hypoxic	hypoxic	JJ	I-NP	O
,	,	,	I-NP	O
parapneumonic	parapneumonic	JJ	I-NP	O
effusions	effusion	NNS	I-NP	O
were	be	VBD	B-VP	O
considered	consider	VBN	I-VP	O
less	less	RBR	B-ADJP	O
likely	likely	JJ	I-ADJP	O
compared	compare	VBN	B-PP	O
to	to	TO	B-PP	O
worsening	worsen	VBG	B-VP	O
CHF	CHF	NN	B-NP	B-protein
.	.	.	O	O

Given	Give	VBN	B-PP	O
the	the	DT	B-NP	O
concern	concern	NN	I-NP	O
for	for	IN	B-PP	O
CHF	CHF	NN	B-NP	B-protein
,	,	,	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
Lasix	Lasix	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
IV	IV	CD	B-NP	O
approximately	approximately	RB	I-NP	O
one	one	CD	I-NP	O
to	to	TO	I-NP	O
two	two	CD	I-NP	O
doses	dose	NNS	I-NP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
for	for	IN	B-PP	O
large	large	JJ	B-NP	O
volume	volume	NN	I-NP	O
diuresis	diuresis	NN	I-NP	O
,	,	,	O	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
goal	goal	NN	I-NP	O
of	of	IN	B-PP	O
total	total	JJ	B-NP	O
body	body	NN	I-NP	O
balance	balance	NN	I-NP	O
of	of	IN	B-PP	O
2	2	CD	B-NP	O
liters	liter	NNS	I-NP	O
negative	negative	JJ	B-ADJP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
.	.	.	O	O

Over	Over	IN	B-PP	O
the	the	DT	B-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
,	,	,	O	O
his	his	PRP$	B-NP	O
bilateral	bilateral	JJ	I-NP	O
effusions	effusion	NNS	I-NP	O
improved	improve	VBD	B-VP	O
,	,	,	O	O
although	although	IN	B-SBAR	O
there	there	EX	B-NP	O
were	be	VBD	B-VP	O
small	small	JJ	B-NP	O
effusions	effusion	NNS	I-NP	O
noted	note	VBN	B-VP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
chest	chest	NN	I-NP	O
x-ray	x-ray	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
oxygen	oxygen	NN	I-NP	O
requirement	requirement	NN	I-NP	O
decreased	decrease	VBD	B-VP	O
,	,	,	O	O
and	and	CC	O	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
day	day	NN	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
saturating	saturate	VBG	I-VP	O
97-98	97-98	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
1	1	CD	B-NP	O
liter	liter	NN	I-NP	O
.	.	.	O	O

Of	Of	IN	B-PP	O
note	note	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
brought	bring	VBN	I-VP	O
to	to	TO	I-VP	O
ultrasound	ultrasound	VB	I-VP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
planned	planned	JJ	I-NP	O
guided	guide	VBN	I-NP	O
thoracocentesis	thoracocentesis	NN	I-NP	O
,	,	,	O	O
but	but	CC	O	O
the	the	DT	B-NP	O
effusion	effusion	NN	I-NP	B-DNA
sites	site	NNS	I-NP	I-DNA
were	be	VBD	B-VP	O
small	small	JJ	B-ADJP	O
such	such	JJ	B-NP	O
that	that	IN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
context	context	NN	I-NP	O
of	of	IN	B-PP	O
this	this	DT	B-NP	O
clinical	clinical	JJ	I-NP	O
improvement	improvement	NN	I-NP	O
,	,	,	O	O
thoracocentesis	thoracocentesis	NN	B-NP	O
was	be	VBD	B-VP	O
deferred	defer	VBN	I-VP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
maintained	maintain	VBN	I-VP	O
initially	initially	RB	B-ADVP	O
as	as	RB	B-ADVP	O
well	well	RB	I-ADVP	O
with	with	IN	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
and	and	CC	I-NP	O
levofloxacin	levofloxacin	NN	I-NP	O
,	,	,	O	O
although	although	IN	B-SBAR	O
the	the	DT	B-NP	O
vancomycin	vancomycin	NN	I-NP	O
was	be	VBD	B-VP	O
discontinued	discontinue	VBN	I-VP	O
after	after	IN	B-PP	O
four	four	CD	B-NP	O
days	day	NNS	I-NP	O
,	,	,	O	O
and	and	CC	O	O
the	the	DT	B-NP	O
levofloxacin	levofloxacin	NN	I-NP	O
was	be	VBD	B-VP	O
discontinued	discontinue	VBN	I-VP	O
on	on	IN	B-PP	O
discharge	discharge	NN	B-NP	O
-LRB-	-LRB-	NN	I-NP	O
of	of	IN	B-PP	O
note	note	NN	B-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
received	receive	VBD	B-VP	O
10	10	CD	B-NP	O
days	day	NNS	I-NP	O
total	total	JJ	B-ADJP	O
of	of	IN	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	O
starting	start	VBG	B-VP	O
from	from	IN	B-PP	O
3/27/2006	3/27/2006	CD	B-NP	O
at	at	IN	B-PP	O
his	his	PRP$	B-NP	B-DNA
nursing	nurse	VBG	I-NP	O
home	home	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
.	.	.	O	O

Echocardiogram	Echocardiogram	NN	B-NP	O
noted	note	VBD	B-VP	O
an	an	DT	B-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
of	of	IN	B-PP	O
55-60	55-60	CD	B-NP	O
%	%	NN	I-NP	O
with	with	IN	B-PP	O
left	left	JJ	B-NP	O
ventricular	ventricular	JJ	I-NP	O
hypertrophy	hypertrophy	NN	I-NP	O
,	,	,	O	O
consistent	consistent	JJ	B-ADJP	O
with	with	IN	B-PP	O
diastolic	diastolic	JJ	B-NP	O
dysfunction	dysfunction	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
etiology	etiology	NN	I-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
congestive	congestive	JJ	I-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
and	and	CC	O	O
pleural	pleural	JJ	B-NP	O
effusions	effusion	NNS	I-NP	O
was	be	VBD	B-VP	O
therefore	therefore	RB	I-VP	O
thought	think	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
with	with	IN	B-PP	O
RVR	RVR	NN	B-NP	B-protein
.	.	.	O	O

In	In	IN	B-PP	O
terms	term	NNS	B-NP	O
of	of	IN	B-PP	O
follow	follow	NN	B-NP	O
up	up	RP	B-PRT	O
,	,	,	O	O
he	he	PRP	B-NP	O
needs	need	VBZ	B-VP	O
daily	daily	JJ	B-NP	O
weights	weight	NNS	I-NP	O
;	;	:	O	O
if	if	IN	B-SBAR	O
he	he	PRP	B-NP	O
gains	gain	VBZ	B-VP	O
greater	great	JJR	B-NP	O
than	than	IN	I-NP	O
2	2	CD	I-NP	O
pounds	pound	NNS	I-NP	O
over	over	IN	B-PP	O
24	24	CD	B-NP	O
hours	hour	NNS	I-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
is	be	VBZ	B-VP	O
recommended	recommend	VBN	I-VP	O
that	that	IN	B-SBAR	O
his	his	PRP$	B-NP	O
Lasix	Lasix	NNP	I-NP	O
dose	dose	NN	I-NP	O
be	be	VB	B-VP	O
doubled	double	VBN	I-VP	O
for	for	IN	B-PP	O
that	that	DT	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

As	As	IN	B-PP	O
a	a	DT	B-NP	O
discharge	discharge	NN	I-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
is	be	VBZ	B-VP	O
being	be	VBG	I-VP	O
sent	send	VBN	I-VP	O
out	out	RP	B-PRT	O
on	on	IN	B-PP	O
Lasix	Lasix	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Cardiovascular	Cardiovascular	NNP	B-NP	O
:	:	:	O	O
a.	a.	NNP	B-NP	O
Ischemia	Ischemia	NNP	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
initially	initially	RB	B-ADVP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
small	small	JJ	I-NP	O
troponin	troponin	NN	I-NP	O
leak	leak	NN	I-NP	O
0.32	0.32	CD	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
thought	think	VBN	I-VP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-VP	O
demand	demand	VB	I-VP	O
ischemia	ischemia	NN	B-NP	O
from	from	IN	B-PP	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
with	with	IN	B-PP	O
RVR	RVR	NN	B-NP	B-protein
.	.	.	O	O

For	For	IN	B-PP	O
this	this	DT	B-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
briefly	briefly	NN	B-NP	O
started	start	VBN	B-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
heparin	heparin	NN	I-NP	B-protein
drip	drip	NN	I-NP	I-protein
.	.	.	O	O

Subsequently	Subsequently	RB	B-ADVP	O
,	,	,	O	O
cardiac	cardiac	JJ	B-NP	B-protein
enzymes	enzyme	NNS	I-NP	I-protein
trended	trend	VBD	B-VP	O
down	down	RB	B-ADVP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
maintained	maintain	VBN	I-VP	O
on	on	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
and	and	CC	I-NP	O
aspirin	aspirin	NN	I-NP	O
81	81	CD	I-NP	O
mg	mg	NN	I-NP	O
,	,	,	O	O
along	along	IN	B-PP	O
with	with	IN	B-PP	O
Zocor	Zocor	NNP	B-NP	O
and	and	CC	I-NP	O
Questran	Questran	NNP	I-NP	O
for	for	IN	B-PP	O
hyperlipidemia	hyperlipidemia	NN	B-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
hospital	hospital	NN	B-NP	O
day	day	NN	I-NP	O
#	#	#	B-NP	O
3	3	CD	I-NP	O
to	to	TO	B-PP	O
#	#	#	B-NP	O
4	4	CD	I-NP	O
,	,	,	O	O
telemetry	telemetry	NN	B-NP	O
noted	note	VBD	B-VP	O
pauses	pause	NNS	B-NP	O
.	.	.	O	O

EKG	EKG	NN	B-NP	B-protein
showed	show	VBD	B-VP	O
in	in	IN	B-PP	O
addition	addition	NN	B-NP	O
to	to	TO	B-PP	O
pausing	pausing	NN	B-NP	O
,	,	,	O	O
new	new	JJ	B-NP	O
T-wave	T-wave	NN	I-NP	O
inversions	inversion	NNS	I-NP	O
in	in	IN	B-PP	O
anterior	anterior	JJ	B-NP	O
precordial	precordial	JJ	I-NP	O
leads	lead	NNS	I-NP	O
,	,	,	O	O
associated	associate	VBN	B-VP	O
with	with	IN	B-PP	O
ST	ST	JJ	B-NP	O
depression	depression	NN	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
is	be	VBZ	B-VP	O
thought	think	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
either	either	CC	O	O
due	due	JJ	B-ADJP	O
to	to	TO	B-PP	O
ischemia	ischemia	NN	B-NP	O
or	or	CC	I-NP	O
digitalis	digitalis	NN	I-NP	O
toxicity	toxicity	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
digoxin	digoxin	NN	I-NP	O
levels	level	NNS	I-NP	O
measured	measure	VBD	B-VP	O
1.3	1.3	CD	B-NP	O
to	to	TO	B-PP	O
1.4	1.4	CD	B-NP	O
,	,	,	O	O
so	so	RB	B-NP	O
digoxin	digoxin	NN	I-NP	O
was	be	VBD	B-VP	O
held	hold	VBN	I-VP	O
,	,	,	O	O
with	with	IN	B-PP	O
improving	improve	VBG	B-VP	O
in	in	IN	B-PP	O
pausing	pausing	NN	B-NP	O
,	,	,	O	O
but	but	CC	O	O
no	no	DT	B-NP	O
change	change	NN	I-NP	O
in	in	IN	B-PP	O
T-wave	T-wave	NN	B-NP	O
inversions	inversion	NNS	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
discussions	discussion	NNS	B-NP	O
with	with	IN	B-PP	O
his	his	PRP$	B-NP	O
outpatient	outpatient	NN	I-NP	O
cardiologist	cardiologist	NN	I-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
thought	think	VBN	I-VP	O
that	that	IN	B-SBAR	O
his	his	PRP$	B-NP	O
T-wave	T-wave	JJ	I-NP	O
inversions	inversion	NNS	I-NP	O
could	could	MD	B-VP	O
possible	possible	JJ	I-VP	O
be	be	VB	I-VP	O
ischemic	ischemic	JJ	B-ADJP	O
,	,	,	O	O
although	although	IN	B-SBAR	O
the	the	DT	B-NP	O
appropriate	appropriate	JJ	I-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
action	action	NN	B-NP	O
was	be	VBD	B-VP	O
not	not	RB	O	O
to	to	TO	B-VP	O
pursue	pursue	VB	I-VP	O
further	further	JJ	B-NP	O
anticoagulation	anticoagulation	NN	I-NP	O
or	or	CC	I-NP	O
evaluation	evaluation	NN	I-NP	O
for	for	IN	B-PP	O
catheterization	catheterization	NN	B-NP	O
,	,	,	O	O
given	give	VBN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
other	other	JJ	I-NP	O
medical	medical	JJ	I-NP	O
issues	issue	NNS	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
maintained	maintain	VBN	I-VP	O
on	on	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
,	,	,	O	O
aspirin	aspirin	NN	B-NP	O
,	,	,	O	O
Zocor	Zocor	NNP	B-NP	O
,	,	,	O	O
Questran	Questran	NNP	B-NP	O
,	,	,	O	O
and	and	CC	O	O
Lopressor	Lopressor	NN	B-NP	B-protein
.	.	.	O	O

b.	b.	JJ	B-NP	O
Rhythm	Rhythm	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
continued	continue	VBD	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
in	in	IN	B-PP	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
throughout	throughout	IN	B-PP	O
his	his	PRP$	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
rate	rate	NN	B-NP	O
controlled	control	VBN	B-VP	O
with	with	IN	B-PP	O
Lopressor	Lopressor	NN	B-NP	B-protein
37.5	37.5	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
t.i.d.	t.i.d.	NN	I-NP	I-protein
-LRB-	-LRB-	NN	I-NP	I-protein
increased	increase	VBD	B-VP	O
from	from	IN	B-PP	O
a	a	DT	B-NP	O
home	home	NN	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
25	25	CD	B-NP	O
mg	mg	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
maintained	maintain	VBN	I-VP	O
on	on	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
2	2	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
for	for	IN	B-PP	O
anticoagulation	anticoagulation	NN	B-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
admission	admission	NN	B-NP	O
,	,	,	O	O
there	there	EX	B-NP	O
was	be	VBD	B-VP	O
a	a	DT	B-NP	O
report	report	NN	I-NP	O
that	that	IN	B-SBAR	O
he	he	PRP	B-NP	O
had	have	VBD	B-VP	O
runs	run	NNS	B-NP	O
of	of	IN	B-PP	O
ventricular	ventricular	JJ	B-NP	O
tachycardia	tachycardia	NN	I-NP	O
and	and	CC	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
lidocaine	lidocaine	NN	I-NP	O
drip	drip	NN	I-NP	O
for	for	IN	B-PP	O
several	several	JJ	B-NP	O
hours	hour	NNS	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
emergency	emergency	NN	I-NP	O
department	department	NN	I-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
documentation	documentation	NN	I-NP	O
regarding	regard	VBG	B-VP	O
telemetry	telemetry	NN	B-NP	O
strips	strip	NNS	I-NP	O
or	or	CC	O	O
QRS	QRS	NNS	B-NP	B-protein
morphologies	morphology	NNS	I-NP	O
could	could	MD	B-VP	O
be	be	VB	I-VP	O
obtained	obtain	VBN	I-VP	O
to	to	TO	I-VP	O
verify	verify	VB	I-VP	O
this	this	DT	B-NP	O
rhythm	rhythm	NN	I-NP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
.	.	.	O	O

In	In	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
throughout	throughout	IN	B-PP	O
his	his	PRP$	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
had	have	VBD	B-VP	O
occasional	occasional	JJ	B-NP	O
runs	run	NNS	I-NP	O
nonsustained	nonsustained	JJ	I-NP	O
VT	VT	NN	I-NP	O
and	and	CC	I-NP	O
SVT	SVT	NN	I-NP	O
.	.	.	O	O

As	As	IN	B-SBAR	O
discussed	discuss	VBN	B-VP	O
above	above	RB	B-ADVP	O
,	,	,	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
thought	think	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
mild	mild	JJ	B-NP	O
digoxin	digoxin	NN	I-NP	O
toxicity	toxicity	NN	I-NP	O
given	give	VBN	B-VP	O
pausing	pause	VBG	B-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
digoxin	digoxin	NN	I-NP	O
level	level	NN	I-NP	O
of	of	IN	B-PP	O
1.3	1.3	CD	B-NP	O
to	to	TO	B-PP	O
1.4	1.4	CD	B-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
digoxin	digoxin	NN	I-NP	O
was	be	VBD	B-VP	O
therefore	therefore	RB	I-VP	O
held	hold	VBN	I-VP	O
and	and	CC	O	O
subsequent	subsequent	JJ	B-NP	O
improvement	improvement	NN	I-NP	O
in	in	IN	B-PP	O
pausing	pausing	NN	B-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
.	.	.	O	O

Of	Of	IN	B-PP	O
note	note	NN	B-NP	O
,	,	,	O	O
on	on	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
his	his	PRP$	B-NP	O
digoxin	digoxin	NN	I-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
discontinued	discontinue	VBN	I-VP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
primary	primary	JJ	I-NP	O
care	care	NN	I-NP	O
physician	physician	NN	I-NP	O
and	and	CC	O	O
cardiologist	cardiologist	NN	B-NP	O
should	should	MD	B-VP	O
consider	consider	VB	I-VP	O
whether	whether	IN	B-SBAR	O
or	or	CC	O	O
not	not	RB	O	O
to	to	TO	B-VP	O
restart	restart	VB	I-VP	O
digoxin	digoxin	NN	B-NP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
.	.	.	O	O

c.	c.	NN	B-NP	O
Pump	Pump	NNP	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
aggressively	aggressively	RB	I-VP	O
diuresed	diurese	VBN	I-VP	O
with	with	IN	B-PP	O
40	40	CD	B-NP	O
mg	mg	NN	I-NP	O
IV	IV	CD	I-NP	O
of	of	IN	B-PP	O
Lasix	Lasix	NNP	B-NP	O
approximately	approximately	RB	B-NP	O
one	one	CD	I-NP	O
to	to	TO	I-NP	O
two	two	CD	I-NP	O
times	time	NNS	I-NP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
,	,	,	O	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
total	total	JJ	I-NP	O
diuresis	diuresis	NN	I-NP	O
of	of	IN	B-PP	O
roughly	roughly	RB	B-NP	O
negative	negative	JJ	I-NP	O
9	9	CD	I-NP	O
liters	liter	NNS	I-NP	O
over	over	IN	B-PP	O
the	the	DT	B-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
.	.	.	O	O

Echocardiogram	Echocardiogram	NN	B-NP	O
showed	show	VBD	B-VP	O
an	an	DT	B-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
of	of	IN	B-PP	O
55-60	55-60	CD	B-NP	O
%	%	NN	I-NP	O
with	with	IN	B-PP	O
left	left	JJ	B-NP	O
ventricular	ventricular	JJ	I-NP	O
hypertrophy	hypertrophy	NN	I-NP	O
,	,	,	O	O
consistent	consistent	JJ	B-ADJP	O
with	with	IN	B-PP	O
diastolic	diastolic	JJ	B-NP	O
dysfunction	dysfunction	NN	I-NP	O
.	.	.	O	O

As	As	IN	B-SBAR	O
discussed	discuss	VBN	B-VP	O
above	above	RB	B-ADVP	O
,	,	,	O	O
he	he	PRP	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
discharged	discharge	VBN	I-VP	O
on	on	IN	B-PP	O
Lasix	Lasix	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

Note	Note	NNP	B-NP	O
,	,	,	O	O
as	as	IN	B-SBAR	O
mentioned	mention	VBN	B-VP	O
above	above	IN	B-PP	O
,	,	,	O	O
if	if	IN	B-SBAR	O
he	he	PRP	B-NP	O
gains	gain	VBZ	B-VP	O
greater	great	JJR	B-NP	O
than	than	IN	I-NP	O
2	2	CD	I-NP	O
pounds	pound	NNS	I-NP	O
over	over	IN	B-PP	O
a	a	DT	B-NP	O
24-hour	24-hour	JJ	I-NP	O
period	period	NN	I-NP	O
,	,	,	O	O
his	his	PRP$	B-NP	O
Lasix	Lasix	NNP	I-NP	O
dose	dose	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
doubled	double	VBN	I-VP	O
for	for	IN	B-PP	O
that	that	DT	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

C.	C.	NNP	B-NP	O
diff	diff	NNP	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
positive	positive	JJ	I-NP	O
C.	C.	NNP	I-NP	O
diff	diff	NN	I-NP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
inpatient	inpatient	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
had	have	VBD	B-VP	O
been	be	VBN	I-VP	O
on	on	IN	B-PP	O
Flagyl	Flagyl	NN	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
nursing	nursing	NN	I-NP	O
home	home	NN	I-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
prior	prior	JJ	I-NP	O
diagnosis	diagnosis	NN	I-NP	O
of	of	IN	B-PP	O
C.	C.	NNP	B-NP	O
diff	diff	NNP	I-NP	O
.	.	.	O	O

Because	Because	IN	B-PP	O
of	of	IN	I-PP	O
persistent	persistent	JJ	B-NP	O
bowel	bowel	NN	I-NP	O
movements	movement	NNS	I-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
switched	switch	VBN	I-VP	O
to	to	TO	B-PP	O
p.o.	p.o.	FW	B-NP	O
vancomycin	vancomycin	NN	I-NP	O
250	250	CD	I-NP	O
mg	mg	NN	I-NP	O
q.i.d.	q.i.d.	RB	B-ADVP	O
,	,	,	O	O
and	and	CC	O	O
upon	upon	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
probiotic	probiotic	JJ	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
Saccharomyces	Saccharomyces	NNP	I-NP	O
boulardii	boulardii	VBD	B-VP	O
250	250	CD	B-NP	O
mg	mg	NN	I-NP	O
q.i.d.	q.i.d.	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
to	to	TO	B-VP	O
replenish	replenish	VB	I-VP	O
his	his	PRP$	B-NP	O
gut	gut	NN	I-NP	O
flora	flora	NN	I-NP	O
.	.	.	O	O

We	We	PRP	B-NP	O
will	will	MD	B-VP	O
recommend	recommend	VB	I-VP	O
that	that	IN	B-SBAR	O
he	he	PRP	B-NP	O
continue	continue	VBP	B-VP	O
p.o.	p.o.	FW	B-NP	O
vancomycin	vancomycin	NN	I-NP	O
and	and	CC	O	O
the	the	DT	B-NP	O
probiotic	probiotic	NN	I-NP	O
for	for	IN	B-PP	O
10	10	CD	B-NP	O
days	day	NNS	I-NP	O
after	after	IN	B-PP	O
his	his	PRP$	B-NP	O
diarrheal	diarrheal	JJ	I-NP	O
symptoms	symptom	NNS	I-NP	O
have	have	VBP	B-VP	O
resolved	resolve	VBN	I-VP	O
.	.	.	O	O

If	If	IN	B-SBAR	O
these	these	DT	B-NP	O
symptoms	symptom	NNS	I-NP	O
do	do	VBP	B-VP	O
not	not	RB	I-VP	O
improve	improve	VB	I-VP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
regimen	regimen	NN	I-NP	O
within	within	IN	B-PP	O
the	the	DT	B-NP	O
few	few	JJ	I-NP	O
days	day	NNS	I-NP	O
following	follow	VBG	B-PP	O
discharge	discharge	NN	B-NP	O
from	from	IN	B-PP	O
Wood	Wood	NNP	B-NP	O
Rehab	Rehab	NNP	I-NP	O
,	,	,	O	O
we	we	PRP	B-NP	O
will	will	MD	B-VP	O
recommend	recommend	VB	I-VP	O
consider	consider	VB	I-VP	O
adding	add	VBG	I-VP	O
metronidazole	metronidazole	NN	B-NP	O
IV	IV	CD	I-NP	O
and	and	CC	O	O
getting	get	VBG	B-VP	O
an	an	DT	B-NP	O
infectious	infectious	JJ	I-NP	O
disease	disease	NN	I-NP	O
consult	consult	NN	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Diabetes	Diabete	NNS	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
several	several	JJ	B-NP	O
bouts	bout	NNS	I-NP	O
of	of	IN	B-PP	O
hypoglycemia	hypoglycemia	NN	B-NP	O
during	during	IN	B-PP	O
the	the	DT	B-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
.	.	.	O	O

These	These	DT	B-NP	O
were	be	VBD	B-VP	O
appeared	appear	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
related	related	JJ	B-ADJP	O
to	to	TO	B-PP	O
poor	poor	JJ	B-NP	O
p.o.	p.o.	NN	I-NP	O
intake	intake	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	B-protein
Lantus	Lantus	NNP	I-NP	O
was	be	VBD	B-VP	O
changed	change	VBN	I-VP	O
to	to	TO	B-PP	O
15	15	CD	B-NP	O
daily	daily	JJ	I-NP	O
,	,	,	O	O
and	and	CC	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
covered	cover	VBN	I-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
NovoLog	NovoLog	NNP	I-NP	O
sliding	slide	VBG	I-NP	O
scale	scale	NN	I-NP	O
.	.	.	O	O

After	After	IN	B-SBAR	O
the	the	DT	B-NP	O
changes	change	NNS	I-NP	O
,	,	,	O	O
his	his	PRP$	B-NP	O
fingersticks	fingerstick	NNS	I-NP	O
ranged	range	VBD	B-VP	O
in	in	IN	B-PP	O
mid	mid	NN	B-NP	O
100	100	CD	I-NP	O
's	's	POS	B-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Hypothyroidism	Hypothyroidism	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
TSH	TSH	NN	I-NP	O
was	be	VBD	B-VP	O
low	low	JJ	B-ADJP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
normal	normal	JJ	I-NP	O
free	free	JJ	I-NP	O
T4	T4	NN	I-NP	O
suggestive	suggestive	JJ	B-ADJP	O
of	of	IN	B-PP	O
sick	sick	JJ	B-NP	O
euthyroid	euthyroid	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
Synthroid	Synthroid	JJ	B-NP	O
25	25	CD	I-NP	O
mcg	mcg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Musculoskeletal	Musculoskeletal	JJ	B-ADJP	O
:	:	:	O	O
Given	Give	VBN	B-VP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
creatinine	creatinine	NN	I-NP	O
clearance	clearance	NN	I-NP	O
of	of	IN	B-PP	O
less	less	JJR	B-NP	O
than	than	IN	I-NP	O
50	50	CD	I-NP	O
,	,	,	O	O
his	his	PRP$	B-NP	O
colchicine	colchicine	NN	I-NP	O
dose	dose	NN	I-NP	O
for	for	IN	B-PP	O
gout	gout	NN	B-NP	O
was	be	VBD	B-VP	O
switched	switch	VBN	I-VP	O
from	from	IN	B-PP	O
0.6	0.6	CD	B-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
to	to	TO	B-PP	O
0.6	0.6	CD	B-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

We	We	PRP	B-NP	O
continued	continue	VBD	B-VP	O
his	his	PRP$	B-NP	O
Neurontin	Neurontin	NN	I-NP	B-protein
for	for	IN	B-PP	O
neuropathic	neuropathic	JJ	B-NP	B-protein
pain	pain	NN	I-NP	I-protein
,	,	,	O	O
and	and	CC	O	O
Tylenol	Tylenol	NN	B-NP	O
for	for	IN	B-PP	O
right	right	JJ	B-NP	O
knee	knee	NN	I-NP	O
osteoarthritis	osteoarthritis	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
seen	see	VBN	I-VP	O
by	by	IN	B-PP	O
Plastic	Plastic	NNP	B-NP	O
Surgery	Surgery	NNP	I-NP	O
registered	register	VBD	B-VP	O
nurse	nurse	NN	B-NP	O
who	who	WP	B-NP	O
recommended	recommend	VBD	B-VP	O
Panafil	Panafil	NNP	B-NP	O
with	with	IN	B-PP	O
dressing	dress	VBG	B-VP	O
for	for	IN	B-PP	O
his	his	PRP$	B-NP	O
right	right	JJ	I-NP	O
heel	heel	NN	I-NP	O
ulcer	ulcer	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
also	also	RB	B-ADVP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
small	small	JJ	I-NP	O
ulcer	ulcer	NN	I-NP	O
developing	develop	VBG	B-VP	O
on	on	IN	B-PP	O
his	his	PRP$	B-NP	O
left	left	JJ	I-NP	O
big	big	JJ	I-NP	O
toe	toe	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
will	will	MD	B-VP	O
need	need	VB	I-VP	O
close	close	JJ	B-NP	O
observation	observation	NN	I-NP	O
as	as	IN	B-PP	O
follow	follow	VB	B-VP	O
up	up	IN	B-PRT	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
Tylenol	Tylenol	NN	B-NP	O
650	650	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.	q.	NN	I-NP	O
8	8	CD	I-NP	O
h.	h.	NN	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
for	for	IN	B-PP	O
headache	headache	NN	B-NP	O
,	,	,	O	O
aspirin	aspirin	NN	B-NP	O
81	81	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
Questran	Questran	NNP	B-NP	O
4	4	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	JJ	I-NP	O
,	,	,	O	O
colchicine	colchicine	NN	B-NP	O
0.6	0.6	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
Nexium	Nexium	NN	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
Lasix	Lasix	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
Neurontin	Neurontin	NNP	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
q.a.m.	q.a.m.	NN	I-NP	O
and	and	CC	O	O
200	200	CD	B-NP	O
mg	mg	NN	I-NP	O
q.p.m.	q.p.m.	NN	I-NP	O
,	,	,	O	O
Lantus	Lantus	NNP	B-NP	O
15	15	CD	I-NP	O
units	unit	NNS	I-NP	O
subq	subq	NN	I-NP	O
at	at	IN	B-PP	O
bedtime	bedtime	NN	B-NP	O
,	,	,	O	O
Synthroid	Synthroid	JJ	B-NP	O
25	25	CD	I-NP	O
mcg	mcg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
Maalox	Maalox	NNP	B-NP	O
one	one	CD	I-NP	O
to	to	TO	B-PP	O
two	two	CD	B-NP	O
tablets	tablet	NNS	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
6	6	CD	I-NP	O
h.	h.	NN	I-NP	O
,	,	,	O	O
metoprolol	metoprolol	NN	B-NP	O
37.5	37.5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
,	,	,	O	O
Panafil	Panafil	NN	B-NP	O
ointment	ointment	NN	I-NP	O
topical	topical	JJ	B-ADJP	O
twice	twice	RB	B-ADVP	O
b.i.d.	b.i.d.	RB	I-ADVP	O
,	,	,	O	O
Saccharomyces	Saccharomyces	NNP	B-NP	O
boulardii	boulardii	VBD	B-VP	O
250	250	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
q.i.d.	q.i.d.	FW	I-ADVP	O
,	,	,	O	O
Zoloft	Zoloft	NNP	B-NP	O
50	50	CD	I-NP	O
mg	mg	NN	I-NP	O
q.a.m.	q.a.m.	NN	I-NP	O
,	,	,	O	O
Zocor	Zocor	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
at	at	IN	B-PP	O
bedtime	bedtime	NN	B-NP	O
,	,	,	O	O
Flomax	Flomax	NN	B-NP	O
0.4	0.4	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	JJ	B-ADJP	O
,	,	,	O	O
vancomycin	vancomycin	NN	B-NP	B-protein
250	250	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	NN	I-NP	I-protein
q.	q.	NN	I-NP	I-protein
6	6	CD	I-NP	I-protein
h.	h.	NN	I-NP	I-protein
,	,	,	O	O
Coumadin	Coumadin	NN	B-NP	O
2	2	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.p.m.	q.p.m.	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
iron	iron	NN	B-NP	O
sulfate	sulfate	NN	I-NP	O
325	325	CD	B-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

eScription	eScription	NN	B-NP	O
document	document	NN	I-NP	O
:	:	:	O	O
2-8888178	2-8888178	CD	B-NP	O
EMSSten	EMSSten	NNP	I-NP	O
Tel	Tel	NNP	I-NP	O
Dictated	Dictated	NNP	I-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
FILIPOVIC	FILIPOVIC	NNP	B-NP	O
,	,	,	O	O
CHANCE	CHANCE	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
BLILER	BLILER	NNP	B-NP	O
,	,	,	O	O
SANTIAGO	SANTIAGO	NNP	B-NP	O
Dictation	Dictation	NNP	I-NP	O
ID	ID	NNP	I-NP	O
5669244	5669244	CD	I-NP	O
D	D	NNP	I-NP	O
:	:	:	O	O
5/26/06	5/26/06	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
5/26/06	5/26/06	CD	B-NP	O

